Urinary kallikrein excretion has been reported to be decreased in patients with essential hypertension and elevated in patients with primary aldosteronism as a reflection of mineralocorticoid activity. Low renin essential hypertension (LREH) has been postulated to result from excess production of an unknown mineralocorticoid(s). Urinary kallikrein excretion was compared in outpatients with essential hypertension, mineralocorticoid hypertension (primary aldosteronism and 17a-hydroxylase deficiency), and in normal subjects of the same race. No significant difference in urinary kallikrein excretion of patients with LREH vs. normal renin essential hypertension (NREH) was found for either black (4.1±0.4 vs. 4.8±0.5 esterase units (EU)/24 h, mean±SE, for 27 LREH and 38 NREH, respectively) or white patients (12.2±2.3 vs. 11.7±1.4 EU/24 h for 13 LREH and 25 NREH, respectively). Urinary kallikrein was decreased in black vs. white hypertensive patients and normal subjects. However, in patients with normal renal function (creatinine clearance ≥80 ml/min) urinary kallikrein was not significantly decreased in either black hypertensive vs. black normal subjects (4.3±0.3 vs. 5.4±0.6 EU/24 h) or in white hypertensive vs. white normal subjects (11.9±1.2 vs. 8.4±0.9 EU/24 h). In contrast, hypertensive patients with mild renal insufficiency (creatinine clearance of 41.8±78.5 ml/min) had reduced (P < 0.05) urinary kallikrein (3.3 EU/24 h with creatinine clearance of 63.6±2.0 for 24 black patients and 4.2±0.7 EU/24 h with creatinine clearance of 67.0±3. (16.3+2.7 vs. 33.3±6.4 ,ug/24 h for black normals) and a failure to achieve metabolic balance in 11/13 patients. Thus, the lesser kallikrein stimulation appeared to result from these two factors. Black and white hypertensives with creatinine clearance <80 ml/min had little increase in urinary kallikrein excretion with Florinef or low sodium diet.
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5 of 12 patients with primary aldosteronism or 17a-hydroxylase deficiency did not have an elevated urinary kallikrein excretion rate. Mild renal insufficiency may have contributed to this finding in two of these five patients. Nevertheless, this finding illustrates a limitation to the use of urinary kallikrein excretion rate as an index of mineralocorticoid activity. However, it appears that the majority of patients with LREH have no evidence for excess production of an unknown mineralocorticoid. The failure to find a decrease in urinary kallikrein excretion in racially matched patients with essential hypertension and normal renal function questions the postulate of a role of the kallikrein-kinin system in the initiation of essential hypertension. Daily refrigerated 24-h urine samples were collected for aldosterone, kallikrein, sodium, potassium, and creatinine determination. Each night the patient retired to bed at 2230-2300 and remained at absolute bed rest from at least 0200 until 0600 when blood was drawn. The fasting patient then ambulated 0600-0800 and blood was again taken for determination of PRA. After a 6-d 10-meq Na+ diet, the fasting patient ambulated 0600-1000 before blood was taken for determina- Table I . Normal 24-h urinary aldosterone excretion (mean+2 SD) determined in normal subjects (Table  II) on their usual diet was 0-15.7 ,ug for black subjects and 1.2-13.4 ,ug for white subjects with a range up to 18.8 and 16.1 ,ug for black and white normal subjects, respectively. Low PRA after 2 h of ambulation or with the intravenous furosemide test (8) is <0.6 and <1.0 ng/ml per h for black and white subjects, respectively. Plasma aldosterone after saline infusion into normal subjects has been reported to fall to <5 (9) or 9 ng/dl (10) or to <25% ofthe base line. The protocol with Florinef administration in conjunction with a 200-meq Na+ diet has also been used as an additional suppressive maneuver to identify patients with primary aldosteronism (Table I) (15) .
INTRODUCTION

RESULTS
The 24-h urinary kallikrein excretion rates for normal subjects and patients with normal renin essential hypertension, LREH, mineralocorticoid hypertension, and mild renal insufficiency (Ccr <80 ml/min) are presented in Tables I and II (Table II) . Kallikrein excretion did not differ between women and men, between normal renin and low renin hypertensive patients, and between normal subjects and hypertensive patients of the same race. However, urinary kallikrein was significantly (P < 0.05) decreased in both white and black patients with essential hypertension and mild renal insufficiency (Table II) FIGURE 1 Urinary kallikrein excretion rate (EU/24 h) in black niormal renin and low renin hypertensive patients, black normal subjects, black patients with primary aldosteronism or 17a-hydroxylase deficiency, and black patients with essential hypertension and mild renal insufficiency (average Ccr of 63.6 ml/min). MIean±2 SD data of the normal subjects are indicated.
or when the two subgroups were combined (r = 0.01-0.08). The normal range for urinary kallikrein excretion (mean±2 SD) was 5.4±6.4 and 8.4± 10.2 EU/24 h for black and white patients, respectively. Urinary kallikrein excretion was elevated in four of five black patients with primary aldosteroniism, in the one black patient with 17a-hydroxylase deficiency, and in two of six white patients with primary aldosteronism. Black normal subjects and hypertensive patients averaged significantly less urinary potassium excretion than white normal subjects and hypertensive patients. Kallikrein excretion did not change in white and black normal subjects and hypertensive patients of different ages (Table III) , though too few subjects above age 60 were available to provide meaningful data above this age (Table III) . PRA with the intravenous furosemide test (8) was lower (P < 0.01) in black vs. white hypertensive patients, as previously reported (8) . Urinary sodium excretion was significantly higher (P < 0.01) in black low renin vs. normal renin patients and in hypertensive black patients vs. hypertensive black patients with imild renal insufficiency. No reasons for these differenices in sodium excretion are apparent. As previously reported (4), there was no correlation of urinary sodium and urinary kallikrein excretion in black (r = 0.01) or white (r = 0.08) normal subjects or black (r = 0.01) or white (r = 0.08) hypertensive patients. Table IV) . A lesser response was noted in low renin black hypertensives. However, these patients had evidence that less sodium depletion was produced because they exhibited a lesser rise in urinary aldosterone excretion, and only 2 or 13 patients had <15 meq sodium/24 h on day 6 of low sodium diet. Thus, the black low renin patients resembled the patients with primary aldosteronism in their failure to achieve sodium balance (Table IV) . In contrast, all normal black subjects achieved balance after a 6-d 10-meq sodium diet. Only one of four white low renin hypertensives had >15 meq sodium/24 h on day 6 of the 10-meq sodium diet.
Further evaluation of the effect of renal function on urinary kallikrein response to Florinef administration and low sodium diet was provided by dividing the black hypertensive patients into those with Ccr <80 ml/min, those with Ccr 80-100 ml/min, and those C, > 100 ml/min (Fig. 7) . There was a progressive increase in urinary kallikrein excretion as renal function improved. The number of white hypertensives in each of these three categories was not adequate to perform a similar detailed analysis.
DISCUSSION
Mechanisms regulating kallikrein excretion remain poorly defined at the present time. Urinary kallikrein excretion increases in nonnal subjects during low sodium diet (4) and in response to mineralocorticoid (4) (19) . This gives a combined incidence of elevated urinary kallikrein excretion in 64% of patients with primary aldosteronism. Increased urinary kallikrein excretion in the one patient with 17a-hydroxylase deficiency is compatible with other observed features of mineralocorticoid excess. We noted a slightly lower incidence (58%) of elevated urinary kallikrein excretion in patients with mineralocorticoid hypertension. The reasons why some patients with primary aldosteronism do not have elevated urinary kallikrein excretion are not apparent. Acquired renal damage in some patients may decrease kallikrein excretion (20) . This factor may have been of special importance in two (Nos. 3 and 5) of our patients and may have contributed to several others (Table I ). The absolute levels of aldosterone should theoretically be of importance. All of our white patients except one (No. 6) had relatively modest elevations in urinary aldosterone; thus, the lower incidence of elevated urinary kallikrein may be related to this. However, one black patient (No. 7) had marked elevations in urinary and plasma aldosterone, normal creatinine clearance, and low urinary kallikrein. This patient is quite elderly (age 69) and, though no effect of age on urinary kallikrein excretion was apparent in Table III , only one patient was past age 65. Deterioration of glomerular, proximal tubular, and distal tubular function has been noted with aging (21, 22) . Because normal urinary kallikrein excretion has not been satisfactorily established for this age group, it is possible that the age factor may have contributed. In addition, the histological type of primary aldosteronism may be of importance in influencing urinary kallikrein excretion. (3, 18, 19) . Thus, the reasons why urinary kallikrein is not increased in Figs. 1 and 2 , and this is not noted. These data are difficult to reconcile with the previously reported increase in unexplained bioassayable mineralocorticoid activity in the urine of most patients with LREH (7) .
The factors which cause urinary kallikrein to increase after mineralocorticoid administration remain unknown. Increased urinary kallikrein excretion may result from a direct effect ofthe mineralocorticoid (24) , as a secondary response to sodium retention induced by the mineralocorticoid, as has been postulated by Adetuyibi and Mills (25) , or indirectly from other mineralocorticoid effects. Since patients with LREH respond favorably to aminoglutethimide with a diuresis (26) while maintaining normokalemia chronically, some have postulated that the etiologic unknown mineralocorticoid induces sodium retention without increasing urinary potassium excretion. If urinary kallikrein increases secondary to sodium retention alone, then our data provide evidence against excess of this postulated different type of unknown sodium-retaining steroid in patients with LREH.
Our failure to find decreased urinary kallikrein excretion in either white or black patients with essential hypertension was unexpected. However, other investigators have subsequently failed to find a decrease in urinary kallikrein excretion in black hypertensive men (16) and in a small group of young white men with normal renin essential hypertension (27) . We confirm the reported (16) decreased urinary kallikrein excretion in black vs. white men and extend these observations to women. It is notable that racial differences may have played a role in the earlier reports (2, 3) of decreased kallikrein excretion in hypertensive patients because this factor was not appreciated at the time. 8 of 11 of these hypertensive patients were reported to be black (3) . The race of an additional 28 hypertensive patients in which urinary kallikrein excretion was measured was not specified. In contrast, 25 of 27 normal subjects were white (4) and the race was not specified in the remaining 30 normal subjects (3) . A recent report (17) from this same group did not note decreased urinary kallikrein excretion in either hypertensive white or black patients, though the number of patients studied (four ofeach race) was too small for adequate evaluation. These data are contrasted to other reports from Italy (19, 28) , Japan (18) , and the United States (16, 20, 29) in which decreased urinary kallikrein was noted in hypertensive patients. The factors which may have led to these conflicts include: (a) racial differences, (b) assay differences, (c) comparison after stimulation with low sodium diet, and (d) inclusion ofpatients with essential hypertension and slight renal insufficiency. On the basis of our data, we feel that this last factor may have been of particular importance. Mitas et al. (20) postulated that decreased kallikrein excretion in hypertensive patients with renal insufficiency may be a primary etiologic factor in the hypertension. However, urinary kallikrein was not determined by these investigators in patients with comparable renal insufficiency but normal blood pressure. Renal kallikrein appears to be localized in distal tubular cells (30) . Urinary kallikrein excretion decreases acutely before the onset of proteinuria in immunologic and aminoglycoside-induced renal injury (31) . In addition, urinary and kidney kallikrein decreases after renal blood flow is diminished by a unilateral renal artery clip. This decrease occurs whether or not hypertension ensues (32 (Fig. 7) .
We have divided hypertensive patients into those with C,. above and below 80 ml/min, as this appears to be the one best dividing line to identify those with decreased renal function when adult men and women up to age 70 are considered (34) . Kallikrein excretion was decreased in both white and black hypertensive patients with Ccr <80 ml/min. When Florinef administration and low sodium diet were used to stimulate kallikrein excretion, the response of normal subjects vs. hypertensive patients with Ccr >80 ml/min was similar except for the low renin hypertensives during low sodium diet. The lesser response in this patient subgroup is likely secondary to the lesser aldosterone stimulation achieved or to some other factor associated with their failure to achieve metabolic balance. The normal kallikrein response of black and white hypertensive patients with normal basal kallikrein excretion to potassium administration (17) also suggests that the renal kallikrein system is initially normal in essential hypertension. However, some investigators (19, 20) have noted decreased urinary kallikrein excretion in white hypertensive patients even when glomerular filtration rate was normal. Inexplicably, one of these groups noted no significant difference in urinary kallikrein excretion in white normals vs. hypertensives during low sodium diet in other studies (16 
